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Abstract  25 
 26 
A clinically reflective model of the human colon was used to investigate the effects of the 27 
broad-spectrum antibiotic omadacycline on the gut microbiome, and subsequent potential to 28 
induce simulated Clostridium difficile infection (CDI). Triple stage chemostat gut models 29 
were inoculated with pooled human faecal slurry IURP KHDOWK\ YROXQWHHUV DJH  \HDUV. 30 
Models were challenged twice with 107 cfu C. difficile spores (PCR ribotype 027). 31 
Omadacycline effects were assessed in a single gut model. Observations were confirmed in a 32 
parallel study with omadacycline and moxifloxacin. Antibiotic instillation was performed 33 
once daily for 7 days. The models were observed for 3 weeks post-antibiotic challenge. Gut 34 
microbiota populations and C. difficile total viable and spore counts were enumerated daily 35 
by culture. Cytotoxin titres and antibiotic concentrations were also measured. Gut microbiota 36 
populations were stable before antibiotic challenge. Moxifloxacin instillation caused a ~4 37 
log10 cfu/mL decline in enterococci and Bacteroides fragilis group populations, and a ~3 38 
log10 cfu/mL decline in bifidobacteria and lactobacilli, followed by simulated CDI (vegetative 39 
cell proliferation and detectable toxin). In both models, omadacycline instillation decreased 40 
populations of bifidobacteria (~8 log10 cfu/mL), B. fragilis group populations (7-8 log10 41 
cfu/mL), lactobacilli (2-6 log10 cfu/mL), and enterococci (4-6 log10 cfu/mL). Despite these 42 
microbial shifts, there was no evidence of C. difficile germination or toxin production. In 43 
contrast to moxifloxacin, omadacycline exposure did not facilitate simulated CDI, suggesting 44 
this antibiotic may have a low propensity to induce CDI in the clinical setting.  45 
46 
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Introduction 47 
 48 
Clostridium difficile infection (CDI) is the leading cause of nosocomial antibiotic-associated 49 
diarrhoea around the world and a major cause of morbidity in the hospitalized elderly (1). 50 
A stable gut microbiota provides colonisation resistance, a key factor in preventing C. 51 
difficile colonisation and proliferation (2). Antibiotic use is a substantial risk factor for CDI 52 
due to the disruption of the microbiota. In particular, broad-spectrum antibiotics represent an 53 
increased CDI risk, especially when these are associated with protracted impairment of 54 
microbiota populations (e.g. fluoroquinolones, cephalosporin and clindamycin) (3, 4). 55 
Omadacycline is a potent aminomethylcycline, with in vitro activity against Gram-positive 56 
and Gram-negative bacteria, including methicillin-susceptible and -resistant Staphylococcus 57 
aureus, coagulase-negative staphylococci, Enterococcus faecalis, Enterococcus faecium, 58 
Streptococcus pneumoniae, Klebsiella pneumoniae, and Bacteroides fragilis (5, 6). 59 
Omadacycline has recently completed phase 3 clinical trials for acute bacterial skin and skin 60 
structure infections and community-acquired bacterial pneumonia (7). Similar to other 61 
tetracyclines, omadacycline inhibits protein synthesis by binding to the 30S ribosomal 62 
subunit, although this novel antimicrobial has been structurally modified to overcome efflux 63 
mechanisms (6, 8). The effect of omadacycline on the normal gut microbiome and 64 
subsequent potential for induction of CDI has not been investigated. 65 
The in vitro gut model has been previously used to study antibiotic predisposition to 66 
simulated CDI using epidemic virulent strains, and the results appear to correlate well with 67 
clinical CDI risk (9). Antibiotics known to have a high propensity to induce CDI clinically 68 
have induced CDI in this model (9-12). Conversely, piperacillin-tazobactam and tigecycline, 69 
antibiotics with a low propensity to induce CDI, did not promote C. difficile germination and 70 
toxin production in the gut model (13, 14). 71 
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This study investigated the effects of omadacycline instillation on the normal gut microbiome 72 
populations and subsequent potential for induction of CDI, in comparison with moxifloxacin. 73 
74 
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Results 75 
 76 
Effects of omadacycline instillation on gut microflora and C. difficile populations 77 
A single triple-stage chemostat model (FIG. S1) containing a stable microbiota derived from 78 
healthy stool samples was used to investigate the effects of omadacycline on the colonic 79 
microflora and propensity of the antibiotic to induce simulated CDI. This gut model, here 80 
referred as OMC, was instilled with a clinically reflective regimen of omadacycline and 81 
microbial populations, including Clostridium difficile total counts and spores, were monitored 82 
daily. Changes in gut microbial populations in vessels 2 and 3 were similar during 83 
omadacycline instillation. Vessel 3 is of most clinical relevance for CDI (see Methods), 84 
therefore results of bacterial enumeration in vessel 3 are shown in FIG. 1, whereas vessel 2 85 
data is presented as supplemental material (FIG. S2). Omadacycline instillation caused a 86 
decline of ~7 log10 cfu/mL in B. fragilis group bacteria (SE±0.16) and a decline of ~8 log10 87 
cfu/mL in bifidobacteria populations (SE±0.14). Both these bacterial populations decreased 88 
to below the limit of detection (~1.2 log10 cfu/mL), in vessel 3 (FIG. 1a). Enterococcus spp. 89 
(SE±0.18) and lactobacilli (SE±0.1) decreased ~4 log10 cfu/ml and ~2 log10 cfu/mL, 90 
respectively (FIG. 1b). Lactose fermenting Enterobacteriaceae populations (SE±0.18) 91 
increased during omadacycline exposure, between 2 log10 cfu/ml in vessel 2 and 1 log10 92 
cfu/ml in vessel 3. Overall, a 2 log decrease in total viable counts (SE±0.18) was observed 93 
following omadacycline exposure, whereas total facultative anaerobic populations (SE±0.25) 94 
remained stable. Recovery of gut microbiota populations was observed 7 days after 95 
omadacycline instillation ended, and populations had returned to steady state levels by the 96 
end of the experiment. 97 
C. difficile total viable counts (TVCs) (SE±0.17) remained roughly equal to spore counts 98 
(SE±0.23) (as distinguished by alcohol tolerance) throughout the experiment in all three 99 
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vessels of OMC, indicating that all C. difficile remained as spores (vessel 3 data shown in 100 
FIG. 1c; vessel 2 data shown in FIG. S2c). Vegetative cell proliferation was not observed and 101 
toxin was not detected in any of the vessels. Simulated CDI did not occur in OMC gut model. 102 
In OMC, mean bioactive omadacycline concentrations peaked at 384 (SE±64.8) mg/L, 163 103 
(SE±30.3) mg/L and 85 (SE±46.7) mg/L in vessels 1, 2 and 3, respectively. Antimicrobial 104 
concentrations in OMC were detectable for 2, 3 and 5 days in vessel 1, 2 and 3, respectively, 105 
in the post antibiotic period. 106 
107 
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In vitro comparison of omadacycline and moxifloxacin propensity to induce CDI   108 
Following the observation that omadacycline did not induce simulated CDI in model OMC, a 109 
pair of gut models comparing omadacycline (OMC1) and moxifloxacin (MOX) exposure was 110 
run. Moxifloxacin has previously been shown to induce simulated CDI in the in vitro gut 111 
model (12), and has been linked to the spread of the epidemic 027 ribotype (15). 112 
Again, population changes in vessel 2 and vessel 3 were similar, so vessel 3 data only is 113 
shown in Figure 2 and 3, whereas vessel 2 data is presented in supplemental Figure 3 and 4 114 
(FIG. S3 and FIG. S4). The addition of C. difficile spores to the gut models did not cause any 115 
variations in the intestinal bacterial populations monitored in OMC1 and MOX.  116 
In OMC1, omadacycline exposure caused declines in B. fragilis group bacteria (SE±0.11) 117 
and bifidobacteria (SE±0.24) of ~8 log10 cfu/mL, to below the limit of detection (FIG. 2a). 118 
Lactobacilli (SE±0.20) and Enterococcus spp. (SE±0.25) populations declined ~6 log10 119 
cfu/mL (FIG. 3a), and lactose fermenting Enterobacteriaceae (SE±0.099) decreased 120 
approximately ~5 log10 cfu/mL. Overall, omadacycline instillation in OMC1 led to a decrease 121 
of ~5 log10 cfu/mL in the total viable counts (SE±0.2), although total facultative anaerobic 122 
populations (SE±0.18) remained fairly stable throughout the experiment, suggesting a decline 123 
of the obligate anaerobic populations. Gut microbiota had returned to steady state levels by 124 
the end of the experiment, with the initial recoveries being observed 9 days after 125 
omadacycline instillation ended. 126 
Moxifloxacin instillation caused marked declines in B. fragilis group populations (SE±0.1), 127 
between ~4 log10 cfu/mL in vessel 3 (FIG. 2b) and ~8 log10 cfu/mL in vessel 2 (FIG. S3b). 128 
Populations of bifidobacteria (SE±0.18) and lactobacilli (SE±0.1) declined ~3 log10 cfu/mL in 129 
both vessels 2 and 3 (FIG. 2b and FIG. S3b, FIG. 3b and FIG. S4b). Enterococci populations 130 
(SE±0.18) also decreased ~4 log10 cfu/mL in both vessels. Lactose fermenting 131 
Enterobacteriaceae populations (SE±0.18) remained stable in vessel 3, but declined ~2 log10 132 
 o
n
 D
ecem
ber 10, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
8 
 
cfu/mL in vessel 2 (FIG. 3b and FIG. S4b). Overall, both obligate (SE±0.14) and facultative 133 
anaerobes (SE±0.19) remained constant during and after moxifloxacin instillation, as 134 
suggested by the total viable counts. Microbiota populations returned to steady state numbers 135 
approximately 1 week after moxifloxacin instillation ended (FIG. 2b and 3b). 136 
137 
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Effect of omadacycline and moxifloxacin on C. difficile 138 
As was observed in OMC, TVCs (SE±0.09) in OMC1 remained similar to spore counts 139 
(SE±0.17) throughout the experiment in all vessels. C. difficile vegetative cell proliferation 140 
was not observed and toxin was not detected (FIG. 4a and FIG. S5a).  141 
In all vessels of MOX gut model, C. difficile remained as spores during the internal control 142 
stage (Period B); however, during moxifloxacin instillation (Period C), an increase in TVCs 143 
(SE±0.16) compared with spore counts (SE±0.16) was observed, corresponding to spore 144 
germination and vegetative cell proliferation. TVCs peaked at ~4.2 log10 cfu/mL on day 30 in 145 
vessel 1 (data not shown), and ~6 log10 cfu/mL in vessel 2 (FIG. S5b) and vessel 3 at day 33 146 
(FIG. 4b). The increase in TVCs was concomitant with the detection of C. difficile cytotoxin, 147 
which reached a peak titre of 2 relative units in vessel 1, and 3 relative units in vessels 2 and 148 
3. Both TVCs and toxin titres decreased towards the end of the experiment, with toxin 149 
undetectable in all vessels by day 42. 150 
 151 
Antimicrobial concentrations in the gut models 152 
Omadacycline concentrations in OMC1 peaked at 242 (SE±41) mg/L, 119 (SE±11.47) mg/L 153 
and 48 (SE±2.78) mg/L in vessels 1, 2 and 3, respectively. Omadacycline remained 154 
detectable for 2 days in vessels 1 and 2 (vessel 2 data shown in FIG. S5a), and for 3 days in 155 
vessel 3 (FIG. 4a), after antibiotic instillation ceased.   156 
Moxifloxacin concentrations peaked at 55 (SE±5.2) mg/L, 34 (SE±2.3) mg/L and 25 (SE±3.3) 157 
mg/L in vessels 1, 2 and 3, respectively, and remained detectable for 2 days in the post 158 
antibiotic period in vessels 1 and 2 (vessel 2 data shown in FIG. S5b), and for 3 days in 159 
vessel 3 (FIG. 4b). 160 
161 
 o
n
 D
ecem
ber 10, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
10 
 
Discussion 162 
 163 
Instillation of omadacycline did not elicit simulated CDI in an in vitro triple-stage chemostat 164 
model (OMC). To further confirm OMC gut model observations, a second experiment was 165 
conducted, where an omadacycline gut model (OMC1) was run in parallel with a model 166 
dosed with moxifloxacin (MOX), in order to compare the potential of each antibiotic to 167 
induce simulated CDI. Despite the fact that gut microbiota dysbiosis appeared more severe 168 
following omadacycline exposure, C. difficile germination and toxin production (simulated 169 
CDI) were observed only in the model instilled with moxifloxacin. The use of different faecal 170 
emulsions to initiate OMC and OMC1 aimed to analyse the effect of the antimicrobial in 171 
unrelated human intestinal microbiota. Similar to expected variation in different individuals, 172 
variations in the extent of the microflora disruption were observed in OMC and OMC1; 173 
however, CDI was not observed in either of the models. 174 
Omadacycline effects on the anaerobic gut microbiota populations were similar in OMC and 175 
OMC1, with all measured anaerobic populations affected, most notably bifidobacteria and B. 176 
fragilis group bacteria, which declined to below the limit of detection. The main differences 177 
between these models were observed during antimicrobial instillation (Period C), in 178 
facultative anaerobic populations. An increase of ~1 log10 cfu/mL in Enterobacteriaceae 179 
populations was observed in OMC, in opposition to the 5 log10 cfu/mL decline observed in 180 
OMC1. This variation is likely to be associated with the different faecal slurry used to initiate 181 
each model. A study investigating 8,345 clinical Enterobacteriaceae isolates has reported 182 
MICs to omadacycline UDQJLQJIURP0PJ/WRPJ/ (16). Given the 183 
complexity of the normal microbiota, the presence of Enterobacteriaceae strains with a wide 184 
range of susceptibilities to omadacycline could explain the differences observed in these 185 
populations during antibiotic instillation in the gut model. Compared with omadacycline, 186 
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moxifloxacin instillation caused a less pronounced decline in B. fragilis group bacteria, 187 
enterococci and lactobacilli populations in vessels 2 and 3, but those were followed by 188 
detection of toxin in all three vessels. This is consistent with previous data (12). 189 
In a Phase I clinical trial, omadacycline metabolism and recovery rates were investigated in 190 
healthy individuals, following the ingestion of the recommended daily oral dose of 300 mg of 191 
antimicrobial (7, 17). Approximately 95% of the antimicrobial was excreted, predominantly 192 
through faeces (mean 81.1%) and urine (14.4%), without drug metabolites being detected. 193 
The highest concentration of omadacycline registered in human faeces in that study was ~430 194 
mg/Kg (unpublished data), which informed the use of a 430mg/L once daily dosing regimen 195 
in this study. Peak omadacycline levels observed in vessel 3 were lower than 430mg/L, 196 
potentially suggesting drug metabolism or sequestration. The lack of metabolites observed in 197 
the faeces clinically (17) indicates sequestration into the biofilm is more likely. Observed 198 
omadacycline concentrations were higher than those determined during moxifloxacin dosing. 199 
Moxifloxacin concentrations observed in vessels 1, 2 and 3 were consistent with the values 200 
reported in previous moxifloxacin gut models (12), and are reflective of gut levels seen in 201 
vivo (18). Microbial recovery in either OMC model was observed between 7-9 days post 202 
cessation of omadacycline. 203 
The observations in our triple-stage model have been shown to correlate with clinical 204 
observations of antimicrobial propensity to induce CDI in vivo (9-14), and have changed UK 205 
national antibiotic prescribing guidelines (19). Antibiotics, such as cephalosporins (9), 206 
clindamycin (10), co-amoxyclav (11), or fluoroquinolones (12), known to have a high 207 
propensity to induce CDI clinically, have induced CDI in this model. Similarly, piperacillin-208 
tazobactam (13) and tigecycline (14), two antibiotics considered of µORZ-ULVN¶ IRU &',209 
clinically, have not induced simulated CDI in the gut model. An intact colonic microbiota has 210 
an important role in protecting the organism against intestinal bacterial pathogens (2, 20). 211 
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Broad-spectrum antibiotic therapy causes a decline of the commensal microflora, leading to a 212 
diminution of microbiota diversity and the subsequent opportunity for the outgrowth of 213 
pathogens such as C. difficile (3, 4). Notably, the gut model studies that investigated 214 
piperacillin-tazobactam (13) and tigecycline (14) also observed a significant decrease in 215 
intestinal microflora populations, and yet an absence of induction of CDI. The tigecycline 216 
MIC of the PCR ribotype 027 strain used in this study was 0.06 mg/L, with tigecycline 217 
concentrations remaining above 1 mg/L five days after cessation of antibiotic instillation (14). 218 
In the present study, the omadacycline MIC (0.25 mg/L) of the C. difficile strain added to the 219 
gut model was assessed by the recommended agar dilution method (21) (data not shown). C. 220 
difficile ATCC 700057 (MIC = 1 mg/L) was used as control (22). Omadacycline levels 221 
dropped to below the limit of detection (8 mg/L) at day 34 and 32, in OMC and OMC1, 222 
respectively. While the bioactive concentration of omadacycline remains higher than the 223 
strain MIC, it would be expected that any C. difficile spore outgrowth would be prevented; 224 
however, once the concentrations decrease below the MIC, spore outgrowth and vegetative 225 
cell proliferation would no longer be prevented. This is observed following clindamycin 226 
exposure in the gut model. A C. difficile strain with a clindamycin MIC of 0.5 mg/L does not 227 
germinate during clindamycin instillation (10), but CDI is consistently observed in the post-228 
antibiotic period. Once clindamycin levels fall below the limit of detection (typically around 229 
5-7 days post instillation), C. difficile vegetative proliferation and toxin are observed. It is 230 
possible that omadacycline, tigecycline and piperacillin-tazobactam intrinsic activity against 231 
C. difficile persists long enough to prevent its proliferation, even when a potential niche has 232 
been created by antibiotic exposure. Baines et al. (13) have previously proposed that the 233 
biofilm formed on the walls of the vessels may contribute to the swift recovery of the 234 
bacterial populations in the gut model and operate as bacterial reservoir during antimicrobial 235 
dosing. It is possible that the biofilm formed in the chemostat model can also contribute to 236 
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the persistence of the drug to a concentration higher than 0.25 mg/L, sufficient to inhibit C. 237 
difficile spore germination and therefore prevent simulated CDI in the gut model. 238 
Sequestration of fidaxomicin into the biofilm of the gut model has previously been observed 239 
and hypothesised to contribute to the prolonged detection of fidaxomicin in the gut model and 240 
patient stool (23). Moreover, the relatively rapid reconstitution of gut microflora populations 241 
after cessation of antimicrobial will provide further protection against CDI.  242 
Despite the disruptive effects of omadacycline to the colonic microflora, when compared 243 
with the present and previous gut model studies, our data suggest that omadacycline may 244 
have a lower-risk for CDI induction than moxifloxacin and other fluoroquinolones. These 245 
observations agree with published studies focusing on the impact of antibiotic exposure on 246 
CDI risk in hospital (24) and community settings (25), which reported tetracyclines to be 247 
among the classes of antimicrobials with lowest risk for CDI induction (26). Furthermore, in 248 
a recent phase 3 community acquired pneumonia clinical trial, there were no cases of CDI 249 
observed in patients treated with omadacycline, compared with eight cases (2%) in those who 250 
received moxifloxacin (27). Further human in vivo data are needed to confirm these 251 
observations suggesting a low CDI propensity for omadacycline. 252 
253 
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Materials and Methods 254 
 255 
Gut model 256 
Three triple-stage chemostat gut models were assembled to simulate CDI, as previously 257 
described (13). Briefly, three glass vessels were arranged in a weir cascade formation and 258 
maintained at 37°C and pH controlled to represent the proximal (vessel 1= 5.5±0.2), medial 259 
(vessel 2= 6.2±0.2) and distal (vessel 3= 6.8±0.2) human colonic environment (FIG. S1). 260 
Vessel 1 has an operating volume of 280 mL, whereas vessels 2 and 3 operate at 300 mL, 261 
each vessel simulating the nutrient availability and alkalinity observed in the area of the colon 262 
represented. An anaerobic environment is achieved by sparging the system with nitrogen and 263 
a complex growth media (13) connected to vessel 1 at a pre-established rate of 0.015h-1 264 
ensures nourishment. The microbial abundance within the gut model has previously been 265 
validated against the intestinal contents of sudden-death victims, and it provides a close 266 
simulation of bacterial activities and composition in different areas of the colon (28). In vivo 267 
studies have shown the distal colon to be severely affected during human CDI (29); thus in 268 
our model, vessel 3 is considered to be most physiologically relevant in terms of propensity 269 
to induce CDI. The gut model has been used to assess in vitro drug efficacy against simulated 270 
CDI at various stages of pre-clinical and clinical drug development, with data from in vitro 271 
models (14, 23) correlating well with data from animal models and Phase III clinical trials 272 
(30-32). 273 
 274 
Experimental design  275 
A gut model experiment (OMC) was conducted to assess the effects of omadacycline in the 276 
intestinal microflora and in C. difficile populations. To confirm the initial observations, a 277 
second assay was later performed. The subsequent experimental design included a new gut 278 
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model exposed to omadacycline (OMC1), run in parallel with a gut model dosed with 279 
moxifloxacin (MOX) (FIG. 5). Moxifloxacin is a broad-spectrum fluoroquinolone that has 280 
been shown to induce simulated CDI in vivo (1) and in the gut model (12). It was also the 281 
comparator antibiotic chosen for the omadacycline phase 3 clinical trial, and therefore was 282 
selected as positive control for induction of simulated CDI, in this study.  283 
OMC model was inoculated with faecal emulsion (10% w/v in pre-reduced PBS) prepared 284 
from C. difficile-negative faeces of three healthy volunteers, while OMC1 and MOX models 285 
were inoculated with a faecal emulsion prepared from C. difficile-negative faeces of five 286 
healthy volunteers. All donors were anonymous, 60 years of age and with no history of 287 
antimicrobial therapy for 3 months. 288 
Following inoculation with faecal emulsion, models were left without intervention for 2 289 
weeks to reach a steady state (Period A). A single 1 ml aliquot of spores (107 cfu/ml) of C. 290 
difficile strain 210 (BI/NAP1/PCR ribotype 027/toxinotype III) (23) was inoculated into 291 
vessel 1 of each model (Period B). Seven days later, at the start of antimicrobial dosing 292 
period, a second inoculum of spores (107 cfu/ml) was added to vessel 1. A PCR ribotype 027 293 
C. difficile strain was chosen for the study due to the clinical relevance of this ribotype. The 294 
210 strain was initially isolated in 2005, during a CDI outbreak at the Maine Medical Centre 295 
(Portland, ME, USA), and was kindly supplied by Dr Robert Owens. Clinically relevant 296 
antimicrobial dosages were used during Period C. Models OMC and OMC1 were dosed with 297 
to 430 mg/L of omadacycline (once daily, 7 days), while model MOX received 43 mg/L of 298 
moxifloxacin (once daily, 7 days). Antimicrobial dosing was adjusted to achieve the desired 299 
concentration in the 280 mL volume of vessel 1. During a Phase I clinical trial, ~80% of a 300 
single oral radiolabelled dose (300 mg) of omadacycline was excreted in the faeces (17). This 301 
equated to a maximum faecal omadacycline concentration of 423000 ngEq/g or ~430mg/Kg 302 
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(unpublished data). A dosing regimen of 430mg/L once daily was therefore used in this study, 303 
equating to 120 mg dosed daily into vessel 1 of the gut model.   304 
Moxifloxacin dosing regimen was performed as previously (12). Moxifloxacin concentration 305 
was based on published data of the concentration of this antimicrobial in human faeces. 306 
Following antimicrobial period, the models were monitored for a further 21 days with no 307 
interventions (Period D).  308 
 309 
Enumeration of endogenous bacteria and quantification of C. difficile toxin  310 
Gut microflora populations were monitored using viable counting on selective and non-311 
selective agars as described previously (33). Populations were measured in triplicate (three 312 
technical replicates of a single biological replicate), in vessels 2 and 3, every other day during 313 
Period A, and daily from period B onwards. C. difficile total viable counts (TVC) and spores 314 
counts were also monitored daily in vessels 1, 2 and 3 throughout the entire experiment 315 
(Periods A±D). Spore counts were obtained through serial dilution and plating of gut model 316 
fluid after alcohol shock. C. difficile cytotoxin was monitored from period B onwards using a 317 
quantitative VERO cell cytotoxicity assay (33). Cytotoxin titres were correlated to an 318 
arbitrary log10 scale and expressed as relative units (RU) at the highest dilution with >70% 319 
cell rounding, i.e. 100=1RU, 10-1=2RU, 10-2=3RU. The limit of detection was ~1.2 log10 320 
cfu/mL for total counts, with exception of total clostridia in OMC where it was 5.2 log10 321 
cfu/mL. The limit of detection for spore counts was ~1.5 log10 cfu/mL and 1 RU for toxin 322 
titre.  323 
 324 
Antimicrobial bioassay 325 
Antimicrobial concentrations in each gut model vessel during periods C and D were 326 
determined using a microbiological bioassay, as described previously (33). Concentrations of 327 
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omadacycline were determined using Wilkins Chalgren agar (Oxoid) with Kocuria rhizophila 328 
as the indicator organism. Concentrations of moxifloxacin were determined using Iso-329 
sensitest agar (Oxoid) with Escherichia coli as the indicator organism.   330 
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FIG 1 Mean (a) obligate anaerobic gut microbiota populations (log10 cfu/mL) including 469 
standard error bars, (b) facultative anaerobic gut microbiota populations (log10 cfu/mL), (c) C. 470 
difficile total viable counts and spore counts (log10 cfu/mL), cytotoxin titres (relative units, 471 
RU) and antimicrobial concentration (mg/L), in vessel 3 of model OMC. Vertical arrows 472 
mark the addition of C. difficile spores to the model, horizontal arrow marks the period of 473 
antibiotic instillation. LF Enterobacteriaceae, lactose-fermenting Enterobacteriaceae; LoD, 474 
limit of detection. 475 
476 
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FIG 2 Mean obligate anaerobic gut microbiota populations (log10 cfu/mL) including standard 477 
error bars, in vessel 3 of (a) model OMC1 (omadacycline dosing), (b) model MOX 478 
(moxifloxacin dosing).  479 
480 
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FIG 3 Mean facultative anaerobic gut microbiota populations (log10 cfu/mL) including 481 
standard error bars, in vessel 3 of (a) model OMC1 (omadacycline dosing), (b) model MOX 482 
(moxifloxacin dosing). LF Enterobacteriaceae, lactose-fermenting Enterobacteriaceae. 483 
484 
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FIG 4 Mean C. difficile total viable counts and spore counts (log10 cfu/mL), cytotoxin titres 485 
(relative units, RU) and antimicrobial concentration (mg/L) in vessel 3 of (a) model OMC1 486 
(omadacycline dosing), (b) model MOX (moxifloxacin dosing). Periods A±D are defined in 487 
Figure 5. Vertical arrows mark the addition of C. difficile spores to the model, horizontal 488 
arrow marks the period of antibiotic instillation. LoD, limit of detection. 489 
490 
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FIG 5 Outline of the gut model experiments with omadacycline (OMC1) and moxifloxacin 491 
(MOX). Asterisks indicate the period when model OMC1 diverged from MOX. CD, C. 492 
difficile spores.  493 
 o
n
 D
ecem
ber 10, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 on December 10, 2018 by guesthttp://aac.asm.org/Downloaded from 
 on December 10, 2018 by guesthttp://aac.asm.org/Downloaded from 
 on December 10, 2018 by guesthttp://aac.asm.org/Downloaded from 
 on December 10, 2018 by guesthttp://aac.asm.org/Downloaded from 
 on December 10, 2018 by guesthttp://aac.asm.org/Downloaded from 
